Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Rani Therapeutics Holdings ( (RANI) ) is now available.
On October 22, 2025, Rani Therapeutics Holdings announced the resignation of board members Andrew Farquharson and Maulik Nanavaty, which was not due to any disagreements with the company. Subsequently, Abraham Bassan and Vasudev Bailey, Ph.D., were appointed to the board, with Bassan becoming chair of the Nominating and Corporate Governance Committee and Bailey chairing the Compensation Committee. Both appointees bring extensive experience in life sciences and healthcare technology. The company also reconstituted its board committees following these changes. On October 23, 2025, Rani Therapeutics completed a private placement of its Class A common stock and warrants, significantly increasing its outstanding shares and potentially impacting its market position.
The most recent analyst rating on (RANI) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Rani Therapeutics Holdings stock, see the RANI Stock Forecast page.
Spark’s Take on RANI Stock
According to Spark, TipRanks’ AI Analyst, RANI is a Underperform.
Rani Therapeutics Holdings’ overall stock score reflects significant financial struggles with no revenue and consistent net losses. The technical analysis shows a bearish trend, and the valuation is challenging with a negative P/E ratio. Strategic advancements in technology and potential partnerships are positive but are overshadowed by financial constraints and high leverage.
To see Spark’s full report on RANI stock, click here.
More about Rani Therapeutics Holdings
Average Trading Volume: 14,271,738
Technical Sentiment Signal: Buy
Current Market Cap: $130.8M
See more data about RANI stock on TipRanks’ Stock Analysis page.